Glutethimide
A sedative-hypnotic medication that was formerly prescribed to treat insomnia by depressing the central nervous system, but has largely been withdrawn from clinical use due to its high potential for abuse, dependence, and dangerous overdose. It shares many of the risks associated with barbiturates and has been replaced by safer sleep medications. Illicitly, it has been abused in combination with codeine.
Molecular Weight
217.2600 g/mol
LogP
1.90
TPSA
46.20 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Structure
Cite this structure
Embed this structure
SMILES
CCC1(c2ccccc2)CCC(=O)NC1=O
InChI
InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)
Molecular Formula
C13H15NO2
HBD / HBA
1 / 2
Rotatable Bonds
2
Heavy Atoms
16
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A sedative-hypnotic medication that was formerly prescribed to treat insomnia by depressing the central nervous system, but has largely been withdrawn from clinical use due to its high potential for abuse, dependence, and dangerous overdose. It shares many of the risks associated with barbiturates and has been replaced by safer sleep medications. Illicitly, it has been abused in combination with codeine.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Glutethimide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1102. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3487. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glutethimide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glutethimide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glutethimide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glutethimide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glutethimide"></drugfyi-drug>